← All trials
NCT05474378
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2022
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Jul 26, 2022
- Last posted
- Jul 26, 2022
- Enrollment
- 39
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversityOverall official - principal investigator
- Stanford UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.